IRLAB to Present Data from the Phase IIb Study of Mesdopetam in PD-LIDs at the MDS Congress 2023

IRLAB Therapeutics AB, a company discovering and developing novel treatments for Parkinson’s disease, announced that the company will present an abstract at the International Congress of Parkinson’s Disease and Movement Disorders®, MDS Congress, in Copenhagen, Denmark from August 27-31, 2023.

Scroll to Top